CA2666814A1 - Combination therapy for treatment of viral infections - Google Patents

Combination therapy for treatment of viral infections Download PDF

Info

Publication number
CA2666814A1
CA2666814A1 CA002666814A CA2666814A CA2666814A1 CA 2666814 A1 CA2666814 A1 CA 2666814A1 CA 002666814 A CA002666814 A CA 002666814A CA 2666814 A CA2666814 A CA 2666814A CA 2666814 A1 CA2666814 A1 CA 2666814A1
Authority
CA
Canada
Prior art keywords
antiviral agent
time period
compound
viral
ifn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002666814A
Other languages
English (en)
French (fr)
Inventor
Roger Jeffs
S. Karl Gotzkowsky
Raymond Allen Dwek
Nicole Zitzmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Oxford
United Therapeutics Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2666814A1 publication Critical patent/CA2666814A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/212IFN-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/45Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002666814A 2006-08-21 2007-08-21 Combination therapy for treatment of viral infections Abandoned CA2666814A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US83887206P 2006-08-21 2006-08-21
US60/838,872 2006-08-21
US87449806P 2006-12-13 2006-12-13
US60/874,498 2006-12-13
US89430707P 2007-03-12 2007-03-12
US60/894,307 2007-03-12
PCT/US2007/076435 WO2008063727A2 (en) 2006-08-21 2007-08-21 Combination therapy for treatment of viral infections

Publications (1)

Publication Number Publication Date
CA2666814A1 true CA2666814A1 (en) 2008-05-29

Family

ID=39426663

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002666814A Abandoned CA2666814A1 (en) 2006-08-21 2007-08-21 Combination therapy for treatment of viral infections

Country Status (6)

Country Link
US (2) US20080131398A1 (enExample)
EP (1) EP2054076A2 (enExample)
JP (1) JP2010510171A (enExample)
KR (1) KR20090057035A (enExample)
CA (1) CA2666814A1 (enExample)
WO (1) WO2008063727A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2356990A3 (en) * 2006-08-02 2011-10-19 University of Oxford Liposome treatment of viral infections
WO2009118658A2 (en) * 2008-03-26 2009-10-01 University Of Oxford Endoplasmic reticulum targeting liposomes
EP2398321B1 (en) 2009-02-23 2015-11-25 United Therapeutics Corporation Iminosugars and methods of treating viral diseases
WO2010099064A1 (en) * 2009-02-24 2010-09-02 United Therapeutics Corporation Iminosugars and methods of treating arenaviral infections
US8703744B2 (en) 2009-03-27 2014-04-22 The Chancellor, Masters And Scholars Of The University Of Oxford Cholesterol level lowering liposomes
ES2524361T3 (es) 2009-06-12 2014-12-05 United Therapeutics Corporation Iminoazúcares para su uso en el tratamiento de enfermedades por bunyavirus y togavirus
CN102625801B (zh) * 2009-09-04 2015-09-09 联合治疗公司 治疗痘病毒感染的方法
ES2466027T3 (es) * 2009-09-04 2014-06-09 United Therapeutics Corporation Procedimiento para el tratamiento de infecciones por ortomixovirus
WO2011028779A1 (en) * 2009-09-04 2011-03-10 United Therapeutics Corporation Iminosugars and methods of treating filoviral diseases
NZ604040A (en) 2010-06-03 2015-02-27 Pharmacyclics Inc The use of inhibitors of bruton’s tyrosine kinase (btk)
US8569255B2 (en) 2011-02-02 2013-10-29 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence Post-exposure therapy of influenza A infections
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
GB2515942A (en) 2011-10-21 2015-01-07 Abbvie Inc Combination treatment (e.g. with ABT-072 or ABT-333) of DAAs for use in treating HCV
PT107894A (pt) 2011-10-21 2014-10-31 Abbvie Inc Métodos para o tratamento de hcv compreendendo pelo menos dois agentes antivirais de actuação directa, ribavirina, mas não interferão.
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
KR20150032340A (ko) 2012-07-24 2015-03-25 파마시클릭스, 인코포레이티드 브루톤 티로신 키나제(btk)의 억제제에 대한 내성과 관련된 돌연변이
EA201590822A1 (ru) 2012-11-02 2016-01-29 Фармасайкликс, Инк. Адъювантная терапия ингибитором киназы семейства tec
JP2017509336A (ja) 2014-03-20 2017-04-06 ファーマサイクリックス エルエルシー ホスホリパーゼcガンマ2及び耐性に関連した変異
US11192914B2 (en) 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
EP3474894A4 (en) * 2016-06-23 2020-02-19 Nutrivert LLC METHODS TO PROMOTE GROWTH AND IMPROVE VALORIZATION OF FOODS IN ANIMALS
FR3057773B1 (fr) * 2016-10-21 2020-06-19 Universite Claude Bernard Lyon 1 Nouvelles compositions antivirales pour le traitement des infections liees aux coronavirus
US10883084B2 (en) 2018-10-05 2021-01-05 Xenotherapeutics, Inc. Personalized cells, tissues, and organs for transplantation from a humanized, bespoke, designated-pathogen free, (non-human) donor and methods and products relating to same
US10799614B2 (en) 2018-10-05 2020-10-13 Xenotherapeutics, Inc. Xenotransplantation products and methods
BR112022019202A2 (pt) 2020-03-26 2022-11-08 Nutrivert Llc Oligopeptídeo, composição farmacêutica, composição, e, método para reduzir a inflamação intestinal em um ser humano, para promover crescimento em um animal e para realçar conversão de alimento em um animal

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6241704B1 (en) * 1901-11-22 2001-06-05 Sims Deltec, Inc. Drug pump systems and methods
US4211771A (en) * 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
US3760984A (en) * 1971-09-29 1973-09-25 Alza Corp Osmotically powered agent dispensing device with filling means
GB1555654A (en) * 1977-06-25 1979-11-14 Exxon Research Engineering Co Agricultural burner apparatus
US4036228A (en) * 1975-09-11 1977-07-19 Alza Corporation Osmotic dispenser with gas generating means
US4016880A (en) * 1976-03-04 1977-04-12 Alza Corporation Osmotically driven active agent dispenser
US4111203A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system with means for improving delivery kinetics of system
US4111202A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
NO154918C (no) * 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
US4203442A (en) * 1977-08-29 1980-05-20 Alza Corporation Device for delivering drug to a fluid environment
DE2834122A1 (de) * 1978-08-03 1980-02-14 Bayer Ag Verfahren zur herstellung von 6-amino-6-desoxy-l-sorbose
US4203440A (en) * 1978-10-23 1980-05-20 Alza Corporation Device having variable volume chamber for dispensing useful agent
DE2853573A1 (de) * 1978-12-12 1980-07-03 Bayer Ag Herstellung von n-substituierten derivaten des l-desoxynojirimycins
US4210139A (en) * 1979-01-17 1980-07-01 Alza Corporation Osmotic device with compartment for governing concentration of agent dispensed from device
US4692147A (en) * 1980-04-02 1987-09-08 Medtronic, Inc. Drug administration device
US4350155A (en) * 1980-04-02 1982-09-21 Medtronic, Inc. Body implantable medical infusion system
US4311137A (en) * 1980-04-30 1982-01-19 Sherwood Medical Industries Inc. Infusion device
DE3038901A1 (de) * 1980-10-15 1982-05-06 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von n-substituierten derivaten des 1-desoxynojirimycins
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US6936694B1 (en) * 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4531937A (en) * 1983-01-24 1985-07-30 Pacesetter Systems, Inc. Introducer catheter apparatus and method of use
US4725852A (en) * 1985-05-09 1988-02-16 Burlington Industries, Inc. Random artificially perturbed liquid apparatus and method
DE3543999A1 (de) * 1985-12-13 1987-06-19 Bayer Ag Hochreine acarbose
US4865845A (en) * 1986-03-21 1989-09-12 Alza Corporation Release rate adjustment of osmotic or diffusional delivery devices
DE3611841A1 (de) * 1986-04-09 1987-10-15 Bayer Ag Verfahren zur herstellung von 1-desoxynojirimycin und dessen n-derivaten
US4861892A (en) * 1988-02-12 1989-08-29 G. D. Searle & Co. Method for synthesis of deoxymannojirimycin
US5017563A (en) * 1988-06-23 1991-05-21 Merrell Dow Pharmaceuticals Inc. Castanospermine esters and glycosides
US4855173A (en) * 1988-08-11 1989-08-08 Dore Peter B Repair process for a fibre reinforced structure
US4910310A (en) * 1988-10-03 1990-03-20 G. D. Searle & Co. Synthesis of N-substituted 1,5-dideoxy-1,5-imino-L-fucitol derivatives
US4894388A (en) * 1988-12-22 1990-01-16 Monsanto Company Glycosidase inhibitors and use thereof
US5011929A (en) * 1989-05-15 1991-04-30 Monsanto Company Synthesis of mannojirimycin derivatives
US5017704A (en) * 1989-06-27 1991-05-21 Monsanto Company Fucosidase inhibitor
US5100797A (en) * 1989-06-27 1992-03-31 Monsanto Company Fucosidase inhibitors
US5043273A (en) * 1989-08-17 1991-08-27 Monsanto Company Phosphorylated glycosidase inhibitor prodrugs
US5112614A (en) * 1989-09-14 1992-05-12 Alza Corporation Implantable delivery dispenser
US4994572A (en) * 1989-10-12 1991-02-19 Monsanto Company Synthesis of nojirimycin derivatives
US4996329A (en) * 1989-10-20 1991-02-26 Monsanto Company Derivatives of 1,4-dideoxy-1,4-imino-D-mannitol and a process for their preparation
US5013842A (en) * 1990-01-22 1991-05-07 Monsanto Company Synthesis of chiral pyrrolidine and piperidine glycosidase inhibitors
US5151519A (en) * 1990-05-07 1992-09-29 G. D. Searle & Co. Process for the preparation of 1,5-(alkylimino)-1,5-dideoxy-d-glucitol and derivatives thereof
US5234692A (en) * 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
US5234693A (en) * 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
ES2087277T3 (es) * 1990-09-20 1996-07-16 Monsanto Co Procedimiento para producir 1-desoxinojirimicina n-sustituida.
US5200523A (en) * 1990-10-10 1993-04-06 Monsanto Company Synthesis of nojirimycin derivatives
US5137727A (en) * 1991-06-12 1992-08-11 Alza Corporation Delivery device providing beneficial agent stability
US5401645A (en) * 1992-03-16 1995-03-28 Monsanto Company Process for producing n-substituted polyhydroxy nitrogen-containing heterocycles utilizing acetobacteraceae and corynebacterium
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5545143A (en) * 1993-01-21 1996-08-13 T. S. I. Medical Device for subcutaneous medication delivery
US5286877A (en) * 1993-02-01 1994-02-15 G. D. Searle & Co. Synthesis of 1,4-dideoxy-1,4-imino-L-arabinitol
US5399567A (en) * 1993-05-13 1995-03-21 Monsanto Company Method of treating cholera
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
ATE186836T1 (de) * 1994-01-13 1999-12-15 Searle & Co Verwendung von 1,5-dideoxy-1,5-imino-d-glucitol n-alkylderivaten zur behandlung von hepatitis b infektionen
WO1995022975A1 (en) * 1994-02-25 1995-08-31 G.D. Searle & Co. Use of 1-deoxynojirimycin and its derivatives for treating mammals infected with respiratory syncytial virus
US5443450A (en) * 1994-04-29 1995-08-22 Medtronic, Inc. Medication delivery device and method of construction
US5559101A (en) * 1994-10-24 1996-09-24 Genencor International, Inc. L-ribofuranosyl nucleosides
DE19509634C1 (de) * 1995-03-17 1996-03-28 Fresenius Ag Implantierbare Infusionspumpe
US5643207A (en) * 1995-04-28 1997-07-01 Medtronic, Inc. Implantable techniques for infusing a therapeutic agent with endogenous bodily fluid
US6387365B1 (en) * 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
PL189289B1 (pl) * 1996-02-02 2005-07-29 Alza Corp Sposób przygotowania implantowanego układu do dostarczania substancji aktywnej
CA2266889A1 (en) * 1996-10-16 1998-04-23 Guangyi Wang Purine l-nucleosides, analogs and uses thereof
UA79749C2 (en) * 1996-10-18 2007-07-25 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
US20030100532A1 (en) * 1997-02-14 2003-05-29 Gary S. Jacob Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy for treating hepatitis virus infections
GB2324223A (en) * 1997-04-11 1998-10-14 Northern Telecom Ltd Network management
US6171276B1 (en) * 1997-08-06 2001-01-09 Pharmacia & Upjohn Ab Automated delivery device and method for its operation
US6172046B1 (en) * 1997-09-21 2001-01-09 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
EP0991415B1 (en) * 1997-12-22 2003-03-12 Schering Corporation Orally administrable solid ribavirin dosage forms and process for making them
US5914128A (en) * 1997-12-22 1999-06-22 Schering Corporation Orally administrable solid dosage form
US6423695B1 (en) * 1998-01-13 2002-07-23 Ribapharm, Inc. Cytokine related treatments of disease
US6689759B1 (en) * 1998-02-12 2004-02-10 G. D. Searle & Co. Methods of Treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy
JP4690545B2 (ja) * 1998-03-31 2011-06-01 バーテックス ファーマシューティカルズ インコーポレイテッド セリンプロテアーゼ、特にc型肝炎ウイルスns3プロテアーゼの阻害因子
US6323180B1 (en) * 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
CN1324250A (zh) * 1998-09-04 2001-11-28 维洛药品公司 治疗或预防病毒感染及其所致疾病的方法
US6277830B1 (en) * 1998-10-16 2001-08-21 Schering Corporation 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon
US6308099B1 (en) * 1998-11-13 2001-10-23 Intermedics Inc. Implantable device and programmer system which permits multiple programmers
ATE402701T1 (de) * 1999-02-12 2008-08-15 United Therapeutics Corp N-(8,8,8-trifluorooctyl)-1,5-dideoxy-1,5-imino- - glucitol zur behandlung von hepatitis-virus- infektionen
US6198966B1 (en) * 1999-02-26 2001-03-06 Medtronic, Inc. Recirculating implantable drug delivery system
US6608027B1 (en) * 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
US7256005B2 (en) * 1999-08-10 2007-08-14 The Chancellor, Masters And Scholars Of The University Of Oxford Methods for identifying iminosugar derivatives that inhibit HCV p7 ion channel activity
US20050119310A1 (en) * 2000-02-14 2005-06-02 Mueller Richard A. Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections
MXPA02009633A (es) * 2000-03-29 2003-03-10 Vertex Pharma Inhibidores de carbamato caspasa y usos de los mismos.
MXPA02000823A (es) * 2000-05-23 2002-07-30 Vertex Pharma Inhibidores de caspasa y uso de los mismos.
DE10031274A1 (de) * 2000-06-27 2002-01-10 Bosch Gmbh Robert Wischarm für Kraftfahrzeuge
GB0110832D0 (en) * 2001-05-03 2001-06-27 Virogen Ltd Antiviral compounds
WO2003032946A2 (en) * 2001-10-12 2003-04-24 United Therapeutics Corporation Ph-sensitive liposomes for targeted drug delivery
US7091184B2 (en) * 2002-02-01 2006-08-15 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
WO2005120479A1 (en) * 2004-06-09 2005-12-22 Gpc Biotech Ag Use of selenium or a selenium salt and a retinoid acid or a retinoid in the treatment of viral hepatitis c
JP2008509902A (ja) * 2004-08-13 2008-04-03 ミジェニックス インコーポレイテッド Hepadnaviridae感染を処置または防止するための組成物および方法
EA200700718A1 (ru) * 2004-10-06 2007-12-28 Мидженикс Инк. Комбинированные противовирусные композиции, содержащие кастаноспермин, и способы их применения
MY141025A (en) * 2004-10-29 2010-02-25 Vertex Pharma Dose forms
CA2597213A1 (en) * 2005-02-09 2006-09-14 Migenix Inc. Compositions and methods for treating or preventing flaviviridae infections
EP2356990A3 (en) * 2006-08-02 2011-10-19 University of Oxford Liposome treatment of viral infections

Also Published As

Publication number Publication date
JP2010510171A (ja) 2010-04-02
KR20090057035A (ko) 2009-06-03
US20080131398A1 (en) 2008-06-05
WO2008063727A3 (en) 2009-01-08
US20130195798A1 (en) 2013-08-01
EP2054076A2 (en) 2009-05-06
WO2008063727A2 (en) 2008-05-29

Similar Documents

Publication Publication Date Title
US20130195798A1 (en) Combination therapy for treatment of viral infections
WO2006016930A2 (en) Methods for treating hcv infection
US7597884B2 (en) Hyperglycosylated polypeptide variants and methods of use
US20100099851A1 (en) Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same
EP2374464A2 (en) HCV N3S-NS4A protease inhibition
CN104023726A (zh) 用于治疗hcv的一种或多种daa的联合治疗(例如,与abt-072或abt-333)
JP2008530124A (ja) フラビウイルス感染症を処置または予防するための組成物および方法
WO2010031832A2 (en) Synergistic combinations of a macrocyclic inhibitor of hcv and a thiophene-2-carboxylic acid derivative
TW201023858A (en) Synergistic combinations of a macrocyclic inhibitor of HCV and a nucleoside
US7932267B2 (en) Use of α-glucosidase inhibitors to treat alphavirus infections
US20070258946A1 (en) Combination Therapy for Treating Hepatitis C Virus Infection
US20040034206A1 (en) Combination therapy for RNA virus infections involving ribavirin and IMPDH inhibitors
EP1007058A1 (en) USE OF $i(N)-SUBSTITUTED-1,5-DIDEOXY-1,5-IMINO-D-GLUCITOL COMPOUNDS IN COMBINATION THERAPY FOR TREATING HEPATITIS VIRUS INFECTIONS
US20100015093A1 (en) Methods and compositions of treating a flaviviridae family viral infection
WO2005062949A2 (en) Method for treating hepatitis virus infection
US11752166B2 (en) Combination therapy for treatment of HCV
US7612093B2 (en) Compositions of treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds in combination therapy
CN101516389A (zh) 用于治疗病毒感染的联合治疗
WO2005110455A2 (en) Combination therapy for treating hepatitis virus infection
WO2005110478A2 (en) Combination therapy for treating fibrotic disorders
US20120148534A1 (en) Methods and compositions of treating a flaviviridae family viral infection
US20230385268A1 (en) Methods for Treating HCV
US20200222397A1 (en) Methods for Treating HCV
Abd Elguaad Study on HCV direct acting drugs in treatment of chronic hepatitis C
NZ609052B2 (en) Methods for treating HCV

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20151112